{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=45", "query": { "intervention": "Placebo- matched", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 7052, "total_pages": 706, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T12:45:28.163Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03069352", "title": "A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2017-05-29", "completion_date": "2025-08-21", "has_results": true, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 6, "location_summary": "Tampa, Florida • Louisville, Kentucky • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03069352" }, { "nct_id": "NCT01682863", "title": "A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "QVA149", "type": "DRUG" }, { "name": "QAB149", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 614, "start_date": "2012-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-03-30", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 47, "location_summary": "Vestavia Hills, Alabama • Huntington Beach, California • Lakewood, California + 43 more", "locations": [ { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Lakewood", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682863" }, { "nct_id": "NCT00788593", "title": "A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Pancreatitis", "Exocrine Pancreatic Insufficiency" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "EUR-1008 (APT-1008) High Dose", "type": "DRUG" }, { "name": "EUR-1008 (APT-1008) Low Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2008-01", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2014-03-12", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Hines", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788593" }, { "nct_id": "NCT04797247", "title": "Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Diseases", "Hyper-LDL-cholesterolemia" ], "interventions": [ { "name": "lerodalcibep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LIB Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2021-04-22", "completion_date": "2024-02-28", "has_results": false, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 3, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04797247" }, { "nct_id": "NCT02322814", "title": "A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2015-03-12", "completion_date": "2021-09-17", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Miami, Florida • Orlando, Florida + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02322814" }, { "nct_id": "NCT06318169", "title": "A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis" ], "interventions": [ { "name": "Pegozafermin", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1350, "start_date": "2024-03-13", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06318169" }, { "nct_id": "NCT07675811", "title": "A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Allergic Conjunctivitis" ], "interventions": [ { "name": "REGN-2Cat", "type": "DRUG" }, { "name": "Freneslerbart", "type": "DRUG" }, { "name": "Mevonlerbart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 570, "start_date": "2026-07-31", "completion_date": "2029-09-20", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 2, "location_summary": "Long Beach, California • Andover, Massachusetts", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675811" }, { "nct_id": "NCT01966419", "title": "Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Episode of Overt Hepatic Encephalopathy", "Hepatic Encephalopathy" ], "interventions": [ { "name": "ornithine phenylacetate", "type": "DRUG" }, { "name": "placebo intravenous infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocera Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 231, "start_date": "2014-01-07", "completion_date": "2016-12-29", "has_results": true, "last_update_posted_date": "2021-09-16", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01966419" }, { "nct_id": "NCT07278492", "title": "NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Down Syndrome (DS)" ], "interventions": [ { "name": "MIB-626", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-08-31", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278492" }, { "nct_id": "NCT07409181", "title": "A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "BI 3000202", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 405, "start_date": "2026-04-20", "completion_date": "2029-07-08", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-11-12T12:45:28.163Z", "location_count": 30, "location_summary": "Beverly Hills, California • La Palma, California • San Diego, California + 27 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07409181" } ] }